Tarlatamab for Patients with Previously Treated Small-Cell . . . ,Virksomhet kataloger , Company Kataloger

companydirectorylist.com Global Business Directories og selskapets kataloger

Country Lister

USA selskap Kataloger

Canada foretak Lister

Australia Business Kataloger

Frankrike Selskapets Lister

Italia Selskapets Lister

Spania Firma Kataloger

Sveits foretak Lister

Østerrike Selskapets Kataloger

Belgia virksomhet kataloger

Hong Kong Selskapets lister

Kina Business Lister

Taiwan Selskapets Lister

De forente arabiske emirater selskapets kataloger

industri Kataloger

USA Industri Kataloger

English Français Deutsch Español 日本語 한국의 繁體简体 Português Italiano Русский हिन्दी ไทย Indonesia Filipino Nederlands Dansk Svenska Norsk Ελληνικά Polska Türkçe العربية

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell
FDA grants traditional approval to tarlatamab-dlle for extensive stage
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc ) for adults with extensive stage s
Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based on Trial . . .
The FDA has granted full approval to tarlatamab, a targeted immunotherapy drug for treating adults with advanced small cell lung cancer (SCLC) that that has spread after platinum-based chemotherapy
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY . . . - Amgen
IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
FDA Fully Approves New Lung Cancer Drug Tarlatamab
Tarlatamab gains full FDA approval for advanced small-cell lung cancer: 40% lower death risk vs chemotherapy — a major step forward
Imdelltra Gains Traditional Approval for Extensive Stage Small Cell . . .
The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with
Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells